BioNTech SE (22UA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioNTech SE (22UA) has a cash flow conversion efficiency ratio of 0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€780.70 Million ≈ $912.72 Million USD) by net assets (€18.48 Billion ≈ $21.60 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioNTech SE - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how BioNTech SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BioNTech SE balance sheet liabilities for a breakdown of total debt and financial obligations.
BioNTech SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioNTech SE ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Reddit, Inc.
NYSE:RDDT
|
0.091x |
|
Circle Internet Group, Inc.
NYSE:CRCL
|
-0.004x |
|
CMS Energy Corporation
NYSE:CMS
|
0.049x |
|
ABN Amro Group NV
AS:ABN
|
0.009x |
|
PulteGroup Inc
NYSE:PHM
|
0.053x |
|
Epiroc AB (publ)
ST:EPI-A
|
0.074x |
|
SAIC Motor Corp Ltd
SHG:600104
|
0.042x |
|
Flex Ltd
NASDAQ:FLEX
|
0.082x |
Annual Cash Flow Conversion Efficiency for BioNTech SE (2017–2024)
The table below shows the annual cash flow conversion efficiency of BioNTech SE from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see BioNTech SE (22UA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €19.41 Billion ≈ $22.69 Billion |
€207.70 Million ≈ $242.82 Million |
0.011x | -95.97% |
| 2023-12-31 | €20.25 Billion ≈ $23.67 Billion |
€5.37 Billion ≈ $6.28 Billion |
0.265x | -60.81% |
| 2022-12-31 | €20.06 Billion ≈ $23.45 Billion |
€13.58 Billion ≈ $15.87 Billion |
0.677x | +805.01% |
| 2021-12-31 | €11.89 Billion ≈ $13.90 Billion |
€889.70 Million ≈ $1.04 Billion |
0.075x | +860.15% |
| 2020-12-31 | €1.37 Billion ≈ $1.60 Billion |
€-13.50 Million ≈ $-15.78 Million |
-0.010x | +97.55% |
| 2019-12-31 | €493.49 Million ≈ $576.94 Million |
€-198.50 Million ≈ $-232.07 Million |
-0.402x | -82.41% |
| 2018-12-31 | €267.00 Million ≈ $312.15 Million |
€-58.88 Million ≈ $-68.83 Million |
-0.221x | -120.22% |
| 2017-12-31 | €-48.21 Million ≈ $-56.36 Million |
€-52.56 Million ≈ $-61.45 Million |
1.090x | -- |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which… Read more